Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Flibanserin as pharmacological therapy of inhibited sexual desire in women

Research output: Contribution to journalReviewResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{0f6dcd756103445fb25b3a6cc91ee381,
title = "Flibanserin as pharmacological therapy of inhibited sexual desire in women",
abstract = "Flibanserin was approved by the Food and Drug Administration in the USA in August 2015 as the first drug for the treatment of American women with the dysfunction hypoactive sexual desire disorder (HSDD) and is a 5-HT1A agonist and 5-HT2A antagonist. The neurophysiological effects of flibanserin on these receptors are consistent with the clinical effects, i.e. significantly increasing sexual desire and frequency of satisfying sexual experiences. As such, shifting the balance between inhibitory and excitatory neurotransmitters of importance to sexual desire, flibanserin pharmacologically broaches a possible new approach to the treatment of HSDD.",
keywords = "Benzimidazoles/pharmacokinetics, Female, Humans, Libido/drug effects, Serotonin 5-HT2 Receptor Antagonists/pharmacology, Serotonin Receptor Agonists/pharmacology, Sexual Dysfunctions, Psychological/drug therapy",
author = "Eldon, {Anne Sofie} and Annamaria Giraldi",
year = "2017",
month = feb,
day = "13",
language = "Dansk",
volume = "179",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "7",

}

RIS

TY - JOUR

T1 - Flibanserin as pharmacological therapy of inhibited sexual desire in women

AU - Eldon, Anne Sofie

AU - Giraldi, Annamaria

PY - 2017/2/13

Y1 - 2017/2/13

N2 - Flibanserin was approved by the Food and Drug Administration in the USA in August 2015 as the first drug for the treatment of American women with the dysfunction hypoactive sexual desire disorder (HSDD) and is a 5-HT1A agonist and 5-HT2A antagonist. The neurophysiological effects of flibanserin on these receptors are consistent with the clinical effects, i.e. significantly increasing sexual desire and frequency of satisfying sexual experiences. As such, shifting the balance between inhibitory and excitatory neurotransmitters of importance to sexual desire, flibanserin pharmacologically broaches a possible new approach to the treatment of HSDD.

AB - Flibanserin was approved by the Food and Drug Administration in the USA in August 2015 as the first drug for the treatment of American women with the dysfunction hypoactive sexual desire disorder (HSDD) and is a 5-HT1A agonist and 5-HT2A antagonist. The neurophysiological effects of flibanserin on these receptors are consistent with the clinical effects, i.e. significantly increasing sexual desire and frequency of satisfying sexual experiences. As such, shifting the balance between inhibitory and excitatory neurotransmitters of importance to sexual desire, flibanserin pharmacologically broaches a possible new approach to the treatment of HSDD.

KW - Benzimidazoles/pharmacokinetics

KW - Female

KW - Humans

KW - Libido/drug effects

KW - Serotonin 5-HT2 Receptor Antagonists/pharmacology

KW - Serotonin Receptor Agonists/pharmacology

KW - Sexual Dysfunctions, Psychological/drug therapy

M3 - Review

C2 - 28397671

VL - 179

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 7

ER -

ID: 55813334